STOCK TITAN

Point72 discloses 2.1% IDEAYA Biosciences (IDYA) stake in 13G/A

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

IDEAYA Biosciences, Inc. attracted institutional interest from Point72-affiliated entities, which reported a 2.1% beneficial stake in the company’s common stock. As of the close of business on December 31, 2025, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen jointly reported beneficial ownership of 1,844,556 shares, with shared voting and dispositive power and no sole authority over any shares.

The shares are held in an investment fund managed by Point72 Asset Management, with Cubist Systematic Strategies, LLC and Point72 (DIFC) Limited acting as sub-advisers for portions of the position. The filers certify the holdings were not acquired to change or influence control of IDEAYA, consistent with a passive Schedule 13G filing and reflecting ownership of 5 percent or less of the class.

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026